Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494831 | 0.81 | KMT2A (0.48) | KMT2AALOX5ATMNPC1RAB9A | |
| SCHEMBL3495038 | 0.81 | PLA2G2A (0.39) | KMT2AATMALDH1A1MEN1 | |
| SCHEMBL3494924 | 0.78 | KMT2A (0.45) | KMT2AALOX5ATMNPC1RAB9A | |
| SCHEMBL3493427 | 0.72 | MEN1 (0.42) | KMT2AATMALDH1A1GAAMEN1 | |
| SCHEMBL491077 | 0.71 | ALDH1A1 (0.62) | KMT2AALDH1A1GAAMEN1 | |
| SCHEMBL8236282 | 0.67 | PDE4B (0.40) | KMT2AALOX5ATMNPC1RAB9A | |
| SCHEMBL491168 | 0.67 | ALOX5 (0.81) | KMT2AALOX5ATMNPC1RAB9A | |
| SCHEMBL3492958 | 0.66 | ALDH1A1 (0.53) | KMT2AALOX5ALDH1A1GAAMEN1 | |
| SCHEMBL3493834 | 0.65 | MAPK1 (0.50) | KMT2AATMALDH1A1GAAMEN1 | |
| SCHEMBL3494815 | 0.65 | NR4A2 (0.46) | KMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | KMT2A 952/4885ALOX5 1064/4885ATM 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.